We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
-7.28%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.53B
AUM Growth
-$382M
(-5.5%)
Cap. Flow
+$195M
Cap. Flow
% of AUM
2.99%
Top 10 Holdings %
Top 10 Hldgs %
59.37%
Holding
305
New
83
Increased
54
Reduced
76
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC Therapeutics
PTCT
|
+$108M |
| 2 |
AB InBev
BUD
|
+$39.8M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
+$33.9M |
| 4 |
Charles River Laboratories
CRL
|
+$32M |
| 5 |
Colgate-Palmolive
CL
|
+$27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$93.3M |
| 2 |
Pfizer
PFE
|
+$76.9M |
| 3 |
Johnson & Johnson
JNJ
|
+$53.7M |
| 4 |
Incyte
INCY
|
+$46.6M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$45.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.38% |
| 2 | Consumer Staples | 6.6% |
| 3 | Technology | 4.23% |
| 4 | Consumer Discretionary | 3.89% |
| 5 | Communication Services | 1.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Tonix Pharmaceuticals
TNXP
$179M
| $790K | 0.01% |
+453
| New | +$1.66M |
|
|
VCNX
152
DELISTED
Vaccinex, Inc. Common Stock
VCNX
| $768K | 0.01% |
+48,571
| New | +$2.47M |
|
153
Acurx Pharmaceuticals
ACXP
$6.32M
| $750K | 0.01% |
25,000
-34,100
| -58% | -$1.3M |
|
154
Zegna
ZGN
$4.08B
| $736K | 0.01% |
+52,874
| New | +$772K |
|
155
Caesars Entertainment
CZR
$6.13B
| $723K | 0.01% |
+15,598
| New | +$829K |
|
156
Inspire Medical Systems
INSP
$1.73B
| $719K | 0.01% |
+3,623
| New | +$914K |
|
157
Ollie's Bargain Outlet
OLLI
$4.74B
| $673K | 0.01% |
+8,724
| New | +$637K |
|
158
Cadrenal Therapeutics
CVKD
$6.07M
| $668K | 0.01% |
+65,486
| New | +$931K |
|
159
Delcath Systems
DCTH
$436M
| $664K | 0.01% |
+164,000
| New | +$769K |
|
160
BJs Wholesale Club
BJ
$12.3B
| $636K | 0.01% |
+8,906
| New | +$599K |
|
161
Onconetix
ONCO
$3.69M
| $577K | 0.01% |
+7
| New | +$1.07M |
|
162
Dropbox
DBX
$8.17B
| $558K | 0.01% |
+20,501
| New | +$559K |
|
|
DRCTW
163
DELISTED
Direct Digital Holdings, Inc. Warrant
DRCTW
| $540K | 0.01% |
900,000
| – | – |
|
164
Cingulate
CING
$66.5M
| $535K | 0.01% |
+3,145
| New | +$512K |
|
|
APCXW
165
DELISTED
AppTech Payments Corp Warrant
APCXW
| $530K | 0.01% |
715,000
| – | – |
|
166
Ulta Beauty
ULTA
$23.2B
| $521K | 0.01% |
+1,304
| New | +$570K |
|
|
ZSTK
167
ZeroStack Corp
ZSTK
$4.52M
| $519K | 0.01% |
+11,478
| New | +$1.04M |
|
|
ELEV
168
DELISTED
Elevation Oncology
ELEV
| $497K | 0.01% |
750,000
-1,646,000
| -69% | -$1.66M |
|
169
Kontoor Brands
KTB
$4.62B
| $495K | 0.01% |
+11,266
| New | +$493K |
|
170
NeuroSense Therapeutics
NRSN
$19.6M
| $470K | 0.01% |
662,000
-604,000
| -48% | -$633K |
|
171
United Rentals
URI
$72.3B
| $455K | 0.01% |
+1,023
| New | +$468K |
|
172
Kroger
KR
$34.7B
| $446K | 0.01% |
+9,977
| New | +$469K |
|
173
Urban Outfitters
URBN
$6.67B
| $443K | 0.01% |
+13,543
| New | +$464K |
|
174
Aptevo Therapeutics
APVO
$5.22M
| $408K | 0.01% |
+2
| New | +$822K |
|
175
Capri Holdings
CPRI
$1.84B
| $392K | 0.01% |
7,443
-62,557
| -89% | -$2.84M |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Armistice Capital held 305 positions worth $6.53B, down 5.5% from $6.91B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Armistice Capital's Q3 2023 filing shows 83 new, 54 increased, 76 reduced and 50 closed positions. Its largest new stake was AB InBev: 703,000 shares worth $38.9M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $93.3M.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 39% a quarter earlier, followed by Consumer Staples and Technology.
- Armistice Capital's largest Q3 2023 buy was AB InBev: 703,000 shares worth $38.9M.
- Armistice Capital added most to PTC Therapeutics in Q3 2023, an estimated $108M increase.
- Armistice Capital's biggest Q3 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $93.3M.
- Armistice Capital fully exited Pfizer in Q3 2023, selling an estimated $76.9M.
- Armistice Capital's ten largest holdings make up 59% of its $6.53B portfolio in Q3 2023.
- Armistice Capital opened 83 new positions and closed 50 in Q3 2023.
- Armistice Capital's portfolio value fell 5.5% quarter-over-quarter to $6.53B.
Based on Armistice Capital's 13F filing for Q3 2023, filed 14 Nov 2023.